The FDA's Shift to One Pivotal Trial Plus Confirmatory Evidence: A New Era of Evidence for Drug Development
Download your copy today
One robust pivotal trial, supported by confirmatory evidence, is emerging as the default pathway for establishing effectiveness — shifting the focus away from the long-standing assumption that two pivotal trials are required.
One of the year’s most significant regulatory policy developments (first announced in February 2026), the FDA’s new draft guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, issued in June 2026, now provides the formal framework.
The central message is not that one trial is automatically enough, rather that trial count matters less than the quality, persuasiveness, relevance, and coherence of the evidence.
This white paper examines the factors that make a single pivotal trial persuasive, the evidence pathways described by the FDA, and the practical implications for clinical development teams, as well as the potential role of real-world evidence (RWE) as confirmatory evidence.
Key topics
- Strength of evidence as the central question
- Considerations for confirmatory RWE
- Choosing an evidence pathway
- Regulatory flexibility and modern evidence sources
- Implications for CRO support
Download your copy today to learn more about this evolving framework and its impact on the future of development planning.
Authors
Jürgen Hummel, Vice President, Innovative Statistics
Evie Merinopoulou, Senior Director, Real World Evidence
Nathalie Horowicz-Mehler, Vice President, EVA Market Access